University of Cincinnati

The General Hospital Corporation

Evangelia Kranias

Roger J Hajjar

Federica Del Monte

Bryan Mitton

Patricia Rodriguez

Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve β-adrenergic responsiveness.

Modulating phosphatase activity in cardiac cells

Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve &#x3b2;-adrenergic responsiveness.

The present invention relates to novel nucleic acids which encode novel mutant forms of Inhibitor Protein-1 (I-1). In particular, the I-1 mutant forms comprise altered phosphorylation sites of PKC-&#x3b1;. In addition, the present invention relates to methods of regulating cardiac contractility and function, and for treatment of cardio myopathy and heart failure, which employ the novel nucleic acids and polypeptides. Vectors comprising the novel nucleic acids, Antibodies to the novel proteins, and diagnostic and screening methods associated therewith, are also provided.

Method for decreasing cardiac using a nucleic acid molecule encoding a variant phosphatase inhibitor-1

The present invention relates to novel nucleic acids which encode novel mutant forms of Inhibitor Protein-1 (1-1). In particular, the 1-1 mutant forms comprise altered phosphorylation sites of PKC-&#x3b1;. In addition, the present invention relates to methods of regulating cardiac contractility and function, and for treatment of cardio myopathy and heart failure, which employ the novel nucleic acids and polypeptides. Vectors comprising the novel nucleic acids, Antibodies to the novel proteins, and diagnostic and screening methods associated therewith, are also provided.

Growing community of inventors

Cincinnati, OH, United States of America

Evangelia Kranias